Oral administered compound colloid pectin bismuth preparation and its preparing process

A technology of colloidal bismuth pectin and compound prescription is applied in the field of oral compound colloidal bismuth pectin preparation and preparation, and can solve the problems of reduced curative effect, poor patient compliance, irritation and the like, and achieve the effects of improving curative effect and reducing toxic and side effects

Active Publication Date: 2005-11-23
SHANXI ZHENDONG ANTE BIOPHARMACEUTICAL CO LTD
View PDF0 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although the above-mentioned bismuth + tetracycline + metronidazole triple therapy, including the triple combination package therapy, has a good effect on eliminating H. Therefore, the adverse reaction rate is high and the patient's compliance is poor
After taking the above drugs, colloidal bismuth pectin and tetracycline exist in the stomach at the same time, and colloidal bismuth pectin can form metal chelates with tetracycline in the stomach, reducing the curative effect, and metronidazole stimulates the stomach

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Colloidal bismuth pectin 5g, tetracycline 1000g, metronidazole 500g;

[0102] Pass 1500g of tetracycline, metronidazole and microcrystalline cellulose through an 80-mesh sieve respectively, mix tetracycline with 1000g of microcrystalline cellulose, metronidazole with 500g of microcrystalline cellulose, and add 1000g of hydroxypropylmethylcellulose to the former for bonding The latter added 500g hydroxypropylmethyl cellulose as a binder, and prepared 40-mesh pellet cores using a centrifugal granulator, and dried at 50°C for 3 hours; after the acrylic resin II was dissolved in ethanol, the acrylic resin II The weight percentage of the ethanol solution is 10%, and castor oil is added to prepare a coating solution; the above-mentioned pellet cores are respectively placed in a coating pan for coating to obtain tetracycline and metronidazole pellets; acrylic resin No. II The weight of the ethanol solution is 100 times of the tetracycline weight, and the weight of the ethanol ...

Embodiment 2

[0106] Colloidal bismuth pectin 335g, tetracycline 125g, metronidazole 125g;

[0107] Its preparation method is the same as Example 1, wherein tetracycline and 200g microcrystalline cellulose, metronidazole and 250g microcrystalline cellulose are mixed evenly, and the former adds 150g hypromellose as binder, and the latter adds 150g hypromellose Base cellulose is the binder.

[0108] The above pellets, colloidal bismuth pectin and excipients in a medically acceptable amount are granulated, dried, and tablet-coated to obtain tablets.

Embodiment 3

[0110] Colloidal bismuth pectin 40g, amoxicillin 5g, tinidazole 1000g;

[0111] The preparation method is the same as in Example 1, wherein: 1510 g of amoxicillin, tinidazole and microcrystalline cellulose are passed through a 120-mesh sieve respectively, amoxicillin and 10 g of microcrystalline cellulose, and tinidazole and 1500 g of microcrystalline cellulose are mixed uniformly, The former adds 5g of hydroxypropyl methylcellulose as a binder, and the latter adds 1500g of hydroxypropylmethylcellulose as a binder. The weight of the ethanol solution of No. Acrylic Resin II is 50 times of the weight of amoxicillin, and the weight of the ethanol solution of No. Acrylic Resin II is 5 times of the weight of tinidazole;

[0112] The above pellets, colloidal bismuth pectin and medically acceptable excipients are granulated, dried, and packed into capsules to obtain capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

Disclosed is an oral administered compound colloid pectin bismuth preparation which comprises colloid pectine bismuth, antibiotics and antibacterial agent. The preparation process comprises dressing antibiotics and antibacterial agent micro-pellet core, mixing with colloid pectine bismuth and medically acceptable amount of excipient. After administration, the colloid pectine bismuth can form a membrane for the protection of gastric mucosa in stomach.

Description

technical field [0001] The invention relates to an oral compound colloidal pectin bismuth preparation for treating peptic ulcer Helicobacter pylori infection, in particular to a triple therapy for treating peptic ulcer Helicobacter pylori infection mainly using colloidal pectin bismuth Oral compound colloid bismuth pectin preparation and preparation method. Background technique [0002] Helicobacter pylori (referred to as Hp) is the main cause of gastric and duodenal ulcers, 80% of gastric ulcers and 90% of duodenal ulcers are caused by Hp, and the WHO has determined that this bacteria is the cause of gastric cancer One of the important reasons. More than 1 / 3 of the world's population is infected with this bacterium. It was recently reported that the infection rate in our population was 61%. About 40-80% of patients with gastric and duodenal ulcers will relapse within 1 year after being treated with existing therapies, but if Hp is eliminated during treatment, only 2% wil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00
Inventor 王金生郑慧哲杨坚
Owner SHANXI ZHENDONG ANTE BIOPHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap